SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
NEW YORK, Dec. 08, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Allergan plc (NYSE:AGN) and/or Actavis plc between February 25, 2014 and November 3, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks recovery of investor losses.
To join the Allergan class action, go to http://www.rosenlegal.com/cases-980.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Allergan and Actavis were engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Allergan and Actavis by the end of 2016 for suspected price collusion; (3) in turn, Allergan and Actavis lacked effective internal controls; and (4) as a result, Allergan plc’s and Actavis plc’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-980.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
